Robert W. Snyder, MD, PhD, PC

1973-1977 Teaching Fellow, Department of Microbiology, University of Utah, Salt Lake City, Utah
1978-1979 Instructor of Microbiology, U.P. Medical Education Program and Adjunct Assistant Professor, Department of Microbiology and Public Health, Michigan State University, East Lansing, Michigan
1988- 1991 Assistant Professor, Department of Ophthalmology, University of Arizona, Tucson, Arizona
1989-1991 Acting Head, Department of Ophthalmology, University of Arizona, Tucson, Arizona
1991-1997 Department Head, Associate Professor, Department of Ophthalmology, University of Arizona
1998- 2004 Department Head and Professor, Department of Ophthalmology, University of Arizona
2003-2022 Professor, Biomedical Engineering, University of Arizona, Tucson, Arizona
2005-2015 Private Practice Ophthalmology at Robert W. Snyder, MD, PhD, PC, Tucson, Arizona
2015-Present Part-time practicing partner at Tucson Eye Care, Tucson, Arizona
2009-Present President, Snyder Biomedical, Tucson, Arizona

Other Experience and Professional Memberships
Special Ad Hoc Review Committee National Eye Institute of the National Institute of Health for Multi-Center Study of Intravenous tPA in Central Vein Occlusion (1989)
Editorial Reviewer
1987-Present Ophthalmology
1987-Present Archives of Ophthalmology
1988-Present Investigative Ophthalmology and Investigative Science
1989 Neuro-Ophthalmology
1990 Diagnostic Microbiology and Infectious Diseases
1991 Refractive and Corneal Surgery
1991-Present American Journal of Ophthalmology
1994-Present Current Eye Research
1995-Present British Journal of Ophthalmology
1996-Present Cornea
1997-Present Ophthalmic Surgery and Lasers
1997-Present Journal of Cataract and Refractive Surgery
2000-Present Life Sciences

State Service
1989-2004 Board of Directors, Arizona Medical Eye Unit
1990-2004 Initiation of and participation in the Lions Sight and Hearing Foundation Cataract Evaluation/Surgery Program
1990-2004 Special Consultant, Arizona Board of Medical Examiners
1992 Medical Officer of the Day, Arizona State Legislature
1992 Delegate to Arizona Medical Association Convention

National Service
1990-2004 Association of University Professors of Ophthalmology, Clinical Care Committee
1994-2004 Member of the Board of the Milwaukee Ophthalmic Institute
1994-2004 Associate Examiner, American Board of Ophthalmology
1994 External Member of ad hoc committee, Five year review of Jules Stein Eye Institute
2003-2004 President , Ocular Microbiology and Immunology Group (OMIG)

International Service
1990 Co-founder, Eye Bank of the Lions Club of Culiacan
1990 Volunteer Surgeon, Lions Club of Culiacan, Cornea Transplant Program
1991 Program Host, Northwest Mexican Ophthalmology Society Meeting
1992 Volunteer, Friends Across the Border Surgery Program
1993 Program Host, Joint Meeting of the Arizona Ophthalmological Society and Northwest Mexican Ophthalmology Society
2001 Pan American Ophthalmology Society, Program Participant
2001 Surgical Eye Expeditions International, International Affiliate

1972-1977 Graduate Fellowship, University of Utah
1987 Copeland Award for Research, Department of Ophthalmology, Medical College of Wisconsin
1989 Award of Recognition, Medical College of Culiacan
1990 Honorary Membership Lions International. In recognition for services to Sight and Hearing
Foundation and Lions Eye Bank
1991 Recognition for Service, Club de Leones de Culiacan, A.C.
1991 Honorary Member Award, Old Pueblo Lions Club
1991-1992 Citizen of the Year Award, Wilmot Lions Club
1992-1993 Recognition Award for Outstanding Dedicated Service, Old Pueblo Lions
1993 In appreciation, Club de Leones del Oeste, Charter Night
1994 Award of Appreciation, Old Pueblo Lions in appreciation for dedicated work in restoring eyesight, Lions Sight and Hearing Foundation Patients
1995 Honorary Member Award, Tucson Breakfast Lions
1996 Humanitarian of the Year, State Lions of Arizona
1996 Distinguished Service Award, Lions Sight and Hearing Foundation
1998-Present Selected by peers to "The Best Doctors in America"
1999 Recognition Award, President’s Club University of Arizona Foundation
2000 Achievement Certificate presented by The Board of Trustees of the American Academy of Ophthalmology, for many years of service to the Academy and its scientific community
2000 Outstanding service and dedication to restoring vision to our patients, Lions Sight and Hearing
2000 Unrestricted/Challenge Grant, Research to Prevent Blindness
2001 Recognition Award, Club de Leones de Ciudad Obregon
2002 Appreciation Award - North American Conference of Lions Foundations
2002 Best Paper Leiter Award - Ocular Microbiology and Immunology Group, Increased Risk of Endophthalmitis in Clear Cornea Cataract Surgery, Snyder, RW, M.D., Ph.D., Nedrud, Chad M.D., Twelker, Dan O.D., Ph.D.

1. My first project addressed intraocular fibrin deposition, the most common cause of failed vitrectomy, when I was in training. I developed an animal model of fibrin deposition and proved the efficacy and safety of intracameral tPA. Within 12-months of completing this project tPA was received FDA approval for human use and within a week we injected the first human with intracameral tPA for an eye filled with fibrin and watched it disperse and clear within an hour, restoring his vision. This became an acceptable procedure for use with post-operative fibrin and some types of hyphemas. My first project at Arizona was also with tPA This was funded by an RO3 grant on steroid-induced glaucoma hypothesizing it was from the downregulation of tPA from the trabecular meshwork in response to corticosteroid treatment. Our research substantiated this finding, but perhaps more importantly led to methods in technology to culture the trabecular meshwork and subsequently we were the first to identify an aquaporin (aquaporin chip 28) in the trabecular meshwork. 

995.   Lambrou FH, Snyder RW, Williams GA: The use of tissue plasminogen activator in experimental hyphema. Arch Ophthalmol. 1987;105:995. 
996.   Snyder RW, Lambrou FH and Williams GA: Intraocular fibrinolysis  with recombinant human tissue plasminogen activator. Arch Ophthalmol. 1987;105:1277-1280. 
997.   Lambrou FH, Snyder RW, Williams GA, Lewandowski M: Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol.  1987;104:619-623.

1. As Chair of the Department of Ophthalmology at The University of Arizona, I set up a number of projects to provide clinical care for underserved populations. Among them was  Proyecto VER which was a collaboration with Dr. Sheila West of Johns Hopkins University. This was a study of eye disease in Mexican-Americans. We discovered that this population had the highest incidence of glaucoma as they aged. As a result of our publications and subsequent lobbying of Congress, Medicare now pays for glaucoma screening for Mexican-Americans from age 55. This was funded by a large multi-center NEI grant.
   1. West SK, Klein R, Rodriguez J, Munoz B, Broman AT, Sanchez R, Snyder R: Diabetes and diabetic retinopathy in a Mexican American population: Proyecto VER.  Diabetes Care. 2001;24:1204-1209.
   2. Munoz B, Sanchez R, West S, Broman A, Rodriguez J, Snyder R, Klein R: Blindness, visual impairment and the problem of uncorrected refractive error in a Mexican-American population: Proyecto VER.  Invest Ophthalmol Vis Sci. 2002;43:608-614.
   3. Broman AT, West SK, Munoz B, Rodriguez J, Sanchez R, Klein R, Snyder R: The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: Proyecto VER.  Invest Ophthalmol Vis Sci.  2002 Nov;43(11):3393-3398.
   4. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R: The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER.  Arch Ophthalmol. 2001;119:1819-1826.
2. More recently, I hypothesized that GPR143 acted as a circadian switch in the retina pigment epithelial cells. Dr. Brian McKay, graduate student Rory Morrison-Colvin, and I performed a number of experiments to validate this approach and I subsequently wrote a patent with Dr. McKay to cover this intellectual property and potentially apply it to use in treatment on patients with macular degeneration with a combination of L-DOPA/carbidopa plus melatonin. We also created a continuous perfusion system to test this that was funded by The University of Arizona Foundation.
   1. Boyd, B, Figueroa, A, Fagan, T, McKay, B, Javid, C., Snyder, RW. Short Term Effects of Carbidopa-Levodopa in Neovascular AMD.  ARVO 2019 
   2. Morrison-Colvin, R, Sillik, S, Congrove, N, McKay, B; Snyder, RW. Circadian Patterns of Secretion of VEGF by RPE. ARVO 2019
3. I designed, secured funding, and completed a "phase 2a" open label proof of concept human trial that shows L-DOPA positively affects nAMD naive to VEGF injection. This was done with the support of local retina specialists.The results were published in 3 presented posters and in a peer reviewed article set for publication in the American Journal of Medicine in January 2021.
   1. Boyd, B, Figueroa, A, Fagan, T, McKay, B, Javid, C., Snyder, RW. Short Term Effects of Carbidopa-Levodopa in Neovascular AMD.  ARVO 2019
   2. Morrison-Colvin, R, Sillik, S, Congrove, N, McKay, B; Snyder, RW. Circadian Patterns of Secretion of VEGF by RPE. ARVO 2019
   3. Figueroa, A, Fagan, T, Boyd, B, Javid, C, McKay, B,., Snyder, RW. Repurposing L-DOPA  for Age Related Macular Degeneration. The Annual Drug Repositioning and Repurposing Conference 2019. 

Figueroa AG, Boyd BM, Christensen CA, et al. Levodopa Positively Affects Neovascular Age-Related Macular Degeneration [published online ahead of print, 2020 Jul 3]. Am J Med. 2020;S0002-9343(20)30539-8. doi:10.1016/j.amjmed.2020.05.038

Federal/National
1987-1988 Principal Investigator: Fight-for-Sight Grant 87-026-Intraocular Fibrinolysis using Human Tissue Plasminogen Activator, $6,400 (90% effort)
1991-1992 Principal Investigator: tPA Activity in Steroid Response Glaucoma, #1203EY099202-01 RO3 grant - National Eye Institute of NIH - $23,045 (80% effort)
1996-1999 Co-investigator: Blindness and Visual Impairment among Mexican Hispanics in Arizona. National Eye Institute of NIH - $3,631,378; Intramural grant from National Eye Institute of NIH. Principal Investigator of clinical site-$959,923 direct (15% effort)
1997-2002 Collaborator: Alpha-2 and Prostaglandin Receptors in the Eye. RO1 grant funded by the NIH - $1,502,553 (5% effort)
Industry
1989 Principal Investigator: Minocycline Therapy for Experimental Blepharitis, Lederle Co. - $6,000 (80% effort)
1989 Principal Investigator: Ciprofloxacin vs. Tobramycin In Treatment of Superficial Eye Infection. Alcon Pharmaceutical - $15,000 (100% effort)
1992 Co-Investigator: Adjunctive Therapy with Galardin Matrix Metalloproteinase Inhibitor (GM 6001) in Patients with Corneal Ulcers Caused by Infection and by Rheumatoid Arthritis. Glycomed - $6,500 (40% effort)
1993 Principal Investigator: Erbium Laser Removal of the Human Lens. Coherent, Inc. - $23,000 direct (85% effort)
1994 Co-Investigator: Localization of Extracellular Matrix Components and Related Degradative Proteolytic Enzymes by Immunofluorescence Confocal Microscopy in the Human Trabecular Meshwork of Glaucomatous Eyes. The Glaucoma Foundation - $7,500 (15% effort
1994 Principal Investigator: A Clinical Evaluation of the Efficacy of BION Tears and Refresh Plus in Moderate to Severe Dry Eye Patients. Alcon Laboratories - $31,725 (85% effort)
1994-1996 Principal Investigator: A One Year, Parallel, Randomized, Double Masked, Active-Controlled, Multi-clinic Study Comparing the Corneal Safety of 2.0% MK-507 Ophthalmic Solution, and 0.5% Betaxolol Ophthalmic Solution in Patients with Elevated Intraocular Pressure with Ocular Hypertension or Glaucoma. Merck Research Laboratories - $69,288 (80% effort)
1994-1998 Principal Investigator: Erbium YAG Laser in Cataract Extraction and Keratectomy. Coherent, Inc. - $49,031(50% effort)
1995 Pre-Residency Fellowship in Ophthalmology. Allergan - $15,000 (100% effort)
1995-1996 Principal Investigator: Corneal Wound Healing with NSAIDs. Allergan - $10,625 (90% effort)
1996-1998 Principal Investigator: Clinical and Surgical Study to Evaluate Efficacy of Keterolac Tromethamine 0.5% Ophthalmic Solution to Prevent Intraoperative Miosis and Postoperative Inflammation in Cataract Surgery. Allergan - $26,250
1998-1999 Principal Investigator: Evaluation of Acular Preservative-Free for the Prevention of Photophobia following Refractive Surgery. Allergan - $38,400
1998-1999 Principal Investigator: Evaluation of Irritation with Topical NSAIDs. Allergan - $10,020
1998-1999 Principal Investigator: Study of Anti-Proliferative Effects of Diclofenac and Ketorolac on Human Lens Epithelial Cells. Allergan - $25,738
Co-Investigator: A Multi-Center, Investigator-Masked, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of Restasis vs. a Masked Artificial Tear (Refresh). Allergan - $16,600
2001-2002 Principal Investigator: A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Analgesic Efficacy of Ketorolac Tromethamine 0.4% Ophthalmic Solution in Post-Photorefractive Keratectomy Patients. Allergan - $27,610.
2003-2004 Principal Investigator: ID 50 of Staph in a Rabbit Endophthalmitis and Keratitis Model. Allergan - $35,000.

Figueroa AG, Boyd BM, Christensen CA, Javid CG, McKay BS, Fagan TC, Snyder RW. Levodopa Positively Affects Neovascular Age-Related Macular Degeneration. Am J Med. 2021 Jan;134(1):122-128.e3. doi: 10.1016/j.amjmed.2020.05.038. Epub 2020 Jul 3. PubMed PMID: 32628915; PubMed Central PMCID: PMC7864558.

Powers LS, Snyder RW, Wardell LJ. Rapid microbial quantification of disinfected contact lens surfaces. Curr Eye Res. 2012 Sep;37(9):850-2. doi: 10.3109/02713683.2012.681095. Epub 2012 Jun 6. PubMed PMID: 22670889.

Oberg TJ, Friday JW, Ursea R, Snyder RW. Is tisseel a viable option in posterior lamellar keratoplasty?. Cornea. 2009 Jul;28(6):681-7. doi: 10.1097/ICO.0b013e3181a2aa5c. PubMed PMID: 19512901.

Slade DS, Friday JW, Snyder RW, Nix DE, Kleinert LB, Patula VB. Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. J Cataract Refract Surg. 2007 May;33(5):888-92. doi: 10.1016/j.jcrs.2007.01.034. PubMed PMID: 17466866.

Sikder S, Snyder RW. Femtosecond laser preparation of donor tissue from the endothelial side. Cornea. 2006 May;25(4):416-22. doi: 10.1097/01.ico.0000195948.86071.98. PubMed PMID: 16670478.

Donnenfeld RS, Perry HD, Solomon R, Jensen HG, Stein J, Snyder RW, Wittpenn JR, Donnenfeld ED. A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model. Eye Contact Lens. 2006 Jan;32(1):46-50. doi: 10.1097/01.icl.0000174761.39015.34. PubMed PMID: 16415694.

Muñoz B, Klein R, Rodriguez J, Snyder R, West SK. Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. Arch Ophthalmol. 2005 Nov;123(11):1575-80. doi: 10.1001/archopht.123.11.1575. PubMed PMID: 16286621.

Broman AT, Hafiz G, Muñoz B, Rodriguez J, Snyder R, Klein R, West SK. Cataract and barriers to cataract surgery in a US Hispanic population: Proyecto VER. Arch Ophthalmol. 2005 Sep;123(9):1231-6. doi: 10.1001/archopht.123.9.1231. PubMed PMID: 16157804.

Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, Bloom A. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005 Mar;112(3):466-9. doi: 10.1016/j.ophtha.2004.09.029. PubMed PMID: 15745775.

Levine JM, Noecker RJ, Lane LC, Herrygers L, Nix D, Snyder RW. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J Cataract Refract Surg. 2004 Oct;30(10):2177-82. doi: 10.1016/j.jcrs.2004.06.048. PubMed PMID: 15474833.

Levine JM, Noecker RJ, Lane LC, Snyder RW, Rapedius M, Blanchard J. Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing. J Ocul Pharmacol Ther. 2004 Jun;20(3):210-6. doi: 10.1089/1080768041223602. PubMed PMID: 15279726.

Broman AT, Munoz B, Rodriguez J, Sanchez R, Quigley HA, Klein R, Snyder R, West SK. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3393-8. PubMed PMID: 12407148.

Schwiegerling J, Snyder RW, Lee JH. Wavefront and topography: keratome-induced corneal changes demonstrate that both are needed for custom ablation. J Refract Surg. 2002 Sep-Oct;18(5):S584-8. PubMed PMID: 12361162.

West SK, Munoz B, Klein R, Broman AT, Sanchez R, Rodriguez J, Snyder R. Risk factors for Type II diabetes and diabetic retinopathy in a mexican-american population: Proyecto VER. Am J Ophthalmol. 2002 Sep;134(3):390-8. doi: 10.1016/s0002-9394(02)01595-7. PubMed PMID: 12208251.

Rodriguez J, Sanchez R, Munoz B, West SK, Broman A, Snyder RW, Klein R, Quigley H. Causes of blindness and visual impairment in a population-based sample of U.S. Hispanics. Ophthalmology. 2002 Apr;109(4):737-43. doi: 10.1016/s0161-6420(01)01008-9. PubMed PMID: 11927431.

Muñoz B, West SK, Rodriguez J, Sanchez R, Broman AT, Snyder R, Klein R. Blindness, visual impairment and the problem of uncorrected refractive error in a Mexican-American population: Proyecto VER. Invest Ophthalmol Vis Sci. 2002 Mar;43(3):608-14. PubMed PMID: 11867574.

Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001 Dec;119(12):1819-26. doi: 10.1001/archopht.119.12.1819. PubMed PMID: 11735794.

West SK, Klein R, Rodriguez J, Muñoz B, Broman AT, Sanchez R, Snyder R. Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Diabetes Care. 2001 Jul;24(7):1204-9. doi: 10.2337/diacare.24.7.1204. PubMed PMID: 11423503.

Broman AT, Munoz B, West SK, Rodriguez J, Sanchez R, Snyder R, Klein R. Psychometric properties of the 25-item NEI-VFQ in a Hispanic population: Proyecto VER. Invest Ophthalmol Vis Sci. 2001 Mar;42(3):606-13. PubMed PMID: 11222517.

Snyder RW, Siekert RW, Schwiegerling J, Donnenfeld E, Thompson P. Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg. 2000 Aug;26(8):1225-7. doi: 10.1016/s0886-3350(00)00439-9. PubMed PMID: 11008052.

Schwiegerling J, Snyder RW. Eye movement during laser in situ keratomileusis. J Cataract Refract Surg. 2000 Mar;26(3):345-51. doi: 10.1016/s0886-3350(99)00435-6. PubMed PMID: 10713227.

Schwiegerling J, Snyder RW. Corneal ablation patterns to correct for spherical aberration in photorefractive keratectomy. J Cataract Refract Surg. 2000 Feb;26(2):214-21. doi: 10.1016/s0886-3350(99)00359-4. PubMed PMID: 10683788.

Levine J, Snyder RW. Practical ophthalmic microbiology. J Ophthalmic Nurs Technol. 1999 Mar-Apr;18(2):50-9; quiz 74-5. Review. PubMed PMID: 10409996.

MacRae S, Schwiegerling J, Snyder RW. Customized and low spherical aberration corneal ablation design. J Refract Surg. 1999 Mar-Apr;15(2 Suppl):S246-8. PubMed PMID: 10202734.

Boswell CA, Noecker RJ, Mac M, Snyder RW, Williams SK. Evaluation of an aqueous drainage glaucoma device constructed of ePTFE. J Biomed Mater Res. 1999;48(5):591-5. doi: 10.1002/(sici)1097-4636(1999)48:5<591::aid-jbm1>3.0.co;2-9. PubMed PMID: 10490671.

Schwiegerling J, Snyder RW. Custom photorefractive keratectomy ablations for the correction of spherical and cylindrical refractive error and higher-order aberration. J Opt Soc Am A Opt Image Sci Vis. 1998 Sep;15(9):2572-9. doi: 10.1364/josaa.15.002572. PubMed PMID: 9729870.

Nichols J, Snyder RW. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol. 1998 Aug;9(4):40-4. doi: 10.1097/00055735-199808000-00007. Review. PubMed PMID: 10387467.

Donnenfeld ED, Perry HD, Snyder RW, Moadel R, Elsky M, Jones H. Intracorneal, aqueous humor, and vitreous humor penetration of topical and oral ofloxacin. Arch Ophthalmol. 1997 Feb;115(2):173-6. doi: 10.1001/archopht.1997.01100150175004. PubMed PMID: 9046250.

Stamer WD, Snyder RW, Regan JW. Characterization of the transmembrane orientation of aquaporin-1 using antibodies to recombinant fusion proteins. Biochemistry. 1996 Dec 17;35(50):16313-8. doi: 10.1021/bi9619536. PubMed PMID: 8973206.

Schwiegerling J, Greivenkamp JE, Miller JM, Snyder RW, Palmer ML. Optical modeling of radial keratotomy incision patterns. Am J Ophthalmol. 1996 Dec;122(6):808-17. doi: 10.1016/s0002-9394(14)70377-0. PubMed PMID: 8956635.

Stamer WD, Huang Y, Seftor RE, Svensson SS, Snyder RW, Regan JW. Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors. Invest Ophthalmol Vis Sci. 1996 Nov;37(12):2426-33. PubMed PMID: 8933759.

Berger JW, Talamo JH, LaMarche KJ, Kim SH, Snyder RW, D'Amico DJ, Marcellino G. Temperature measurements during phacoemulsification and erbium:YAG laser phacoablation in model systems. J Cataract Refract Surg. 1996 Apr;22(3):372-8. doi: 10.1016/s0886-3350(96)80253-7. PubMed PMID: 8778374.

Greivenkamp JE, Mellinger MD, Snyder RW, Schwiegerling JT, Lowman AE, Miller JM. Comparison of three videokeratoscopes in measurement of toric test surfaces. J Refract Surg. 1996 Feb;12(2):229-39. PubMed PMID: 8653525.

Stamer WD, Seftor RE, Snyder RW, Regan JW. Cultured human trabecular meshwork cells express aquaporin-1 water channels. Curr Eye Res. 1995 Dec;14(12):1095-1100. doi: 10.3109/02713689508995815. PubMed PMID: 8974838.

Stamer WD, Seftor RE, Williams SK, Samaha HA, Snyder RW. Isolation and culture of human trabecular meshwork cells by extracellular matrix digestion. Curr Eye Res. 1995 Jul;14(7):611-7. doi: 10.3109/02713689508998409. PubMed PMID: 7587308.

Snyder RW, Glasser DB. Antibiotic therapy for ocular infection. West J Med. 1994 Dec;161(6):579-84. Review. PubMed PMID: 7856158; PubMed Central PMCID: PMC1022739.

Stamer WD, Snyder RW, Smith BL, Agre P, Regan JW. Localization of aquaporin CHIP in the human eye: implications in the pathogenesis of glaucoma and other disorders of ocular fluid balance. Invest Ophthalmol Vis Sci. 1994 Oct;35(11):3867-72. PubMed PMID: 7523327.

Metrikin DC, Allinson RW, Snyder RW. Transscleral repair of recalcitrant, inadvertent, postoperative cyclodialysis cleft. Ophthalmic Surg. 1994 Jun;25(6):406-8. PubMed PMID: 8090426.

Noecker RJ, Allinson RW, Snyder RW. Resident phacoemulsification experience using the in situ nuclear fracture technique. Ophthalmic Surg. 1994 Apr;25(4):216-21. PubMed PMID: 8015772.

Snyder RW, Donnenfeld ED. Teaching phacoemulsification to residents and physicians in transition. Int Ophthalmol Clin. 1994 Spring;34(2):191-9. doi: 10.1097/00004397-199403420-00013. Review. PubMed PMID: 8071019.

Seftor RE, Stamer WD, Seftor EA, Snyder RW. Dexamethasone decreases tissue plasminogen activator activity in trabecular meshwork organ and cell cultures. J Glaucoma. 1994 Winter;3(4):323-8. PubMed PMID: 19920617.

Snyder RW, Stamer WD, Kramer TR, Seftor RE. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res. 1993 Oct;57(4):461-8. doi: 10.1006/exer.1993.1148. PubMed PMID: 8282032.

Allinson RW, Le TD, Kramer TR, Snyder RW. Fluorescein angiographic appearance of Dalen-Fuchs nodules in sympathetic ophthalmia. Ann Ophthalmol. 1993 Apr;25(4):152-6. PubMed PMID: 8484659.

Benson DR, Hemmady PB, Snyder RW. Efficacy of laser punctal occlusion. Ophthalmology. 1992 Apr;99(4):618-21. doi: 10.1016/s0161-6420(92)31928-1. PubMed PMID: 1584580.

Fante RG, Snyder RW, Metrikin DC. Treating dry eye. CLAO J. 1992 Jan;18(1):14. PubMed PMID: 1559283.

Snyder RW, Brenner MB, Wiley L, Yee RW, Gradus MS, Mackman GS. Microbial keratitis associated with plano tinted contact lenses. CLAO J. 1991 Oct;17(4):252-5. PubMed PMID: 1764772.

Snyder RW, Gualtieri CJ, Jahnke JC, Hemmady PB, McDermott ML. Quantitation of scleral tobramycin levels. J Ocul Pharmacol. 1991 Summer;7(2):157-62. doi: 10.1089/jop.1991.7.157. PubMed PMID: 1919271.

Snyder RW, Sherman MD, Allinson RW. Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty. Am J Ophthalmol. 1990 Apr 15;109(4):483-4. doi: 10.1016/s0002-9394(14)74622-7. PubMed PMID: 2109930.

Hemmady P, Snyder RW, Klink M. A hypertensive emergency following cataract extraction and cornea transplantation. Ophthalmic Surg. 1989 Sep;20(9):647-9, Discussion, 650. PubMed PMID: 2812693.

Koenig SB, Snyder RW, Hyndiuk RA. Guarded scalpel for corneal relaxing incision. Cornea. 1989;8(2):155. doi: 10.1097/00003226-198906000-00014. PubMed PMID: 2714097.
Koenig SB, Snyder RW, Kay J. Respiratory distress after a Nadbath block. Ophthalmology. 1988 Sep;95(9):1285-7. doi: 10.1016/s0161-6420(88)33020-4. PubMed PMID: 3211505.

Williams GA, Lambrou FH, Jaffe GA, Snyder RW, Green GD, Devenyi RG, Abrams GW. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol. 1988 Aug;106(8):1055-8. doi: 10.1001/archopht.1988.01060140211025. PubMed PMID: 3135790.

Lambrou FH, Snyder RW, Williams GA, Lewandowski M. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol. 1987 Dec 15;104(6):619-23. doi: 10.1016/0002-9394(87)90175-9. PubMed PMID: 3120591.

Snyder RW, Lambrou FH, Williams GA. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model. Arch Ophthalmol. 1987 Sep;105(9):1277-80. doi: 10.1001/archopht.1987.01060090135044. PubMed PMID: 3115240.

Harris GJ, Snyder RW. Lacrimal gland abscess. Am J Ophthalmol. 1987 Aug 15;104(2):193-4. doi: 10.1016/0002-9394(87)90021-3. PubMed PMID: 3303949.

Lambrou FH, Snyder RW, Williams GA. Use of tissue plasminogen activator in experimental hyphema. Arch Ophthalmol. 1987 Jul;105(7):995-7. doi: 10.1001/archopht.1987.01060070139044. PubMed PMID: 3111453.